Project Grant R01DA063124
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University in St. Louis a Project Grant of $392,648 under the Drug Use and Addiction Research Programs (CFDA 93.279) effective June 12, 2025, with completion targeted for December 31, 2028. This NRSA F32 fellowship grant supports research investigating the role of enkephalin neurons in the dorsal raphe nucleus (DRN) and their contribution to motivational and affective behavioral dysfunction...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, San Diego a $197,500 Project Grant effective September 1, 2025, through August 31, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279). This award supports the development and validation of an in vivo Massively Parallel Reporter Assay (MPRA) designed to analyze the functional role of cis-regulatory elements and genetic variants associated with substance use disorders...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University a Project Grant totaling $1,320,580 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct preclinical and translational research on the analgesic potential of novel peripherally-restricted cannabinoid type 1 receptor (CB1R) ligands. The research addresses the discrepancy between promising preclinical findings and inconsistent clinical outcomes by investigating VIP36,...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University $668,131 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 15, 2025, with a project completion date of April 30, 2030. This Project Grant supports basic neuroscience research investigating the mesolimbic dopamine system adaptations underlying altered reward sensitivity in chronic neuropathic pain (CNP) patients. The research addresses a critical gap in pain...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $386,500 to Tufts University School of Medicine under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 15, 2025, with completion scheduled for August 31, 2027. This R21 project grant funds research investigating the neurobehavioral mechanisms linking fentanyl overdose (OD) to anhedonia—the loss of pleasure or reward motivation—and subsequent relapse risk in individuals with...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Maryland, Baltimore a $275,204 Project Grant on June 12, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research investigating the impact of perinatal fentanyl exposure on dopamine neuron circuitry and behavioral outcomes. The research will deliver scientific knowledge addressing the critical public health challenge of opioid use disorder among pregnant women,...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Children's Hospital of Philadelphia Research Institute a Project Grant totaling $389,816 under the Drug Use and Addiction Research Programs (CFDA 93.279) on June 16, 2025, with completion targeted for January 31, 2027. This two-year research initiative investigates the neural mechanisms underlying fentanyl-linked context memories to develop novel therapeutic approaches for preventing addiction relapse. The...
- Federal Grant Award Summary The University of Cincinnati's Sponsored Research Services Division received a $1.17 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective July 15, 2025, through March 31, 2030. This award supports a multi-omics research initiative investigating single-cell opioid (fentanyl) responses in the context of human immunodeficiency virus (HIV) infection. The project delivers...
- This $495,950 Project Grant awarded by the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) supports a three-year investigation into mu opioid receptor (MOR) mechanisms in the nucleus of the solitary tract (NTS) that contribute to fentanyl-induced cardiorespiratory depression. The research, conducted by The Washington University's Office of Sponsored Research Services from September 1, 2025, through August 31, 2028, will employ...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Massachusetts Medical School a $825,383 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning August 1, 2025, with completion targeted for April 30, 2030. This research project investigates the role of striatal molecular rhythms in sleep disruption and opioid use disorder (OUD), addressing the critical public health challenge of high relapse rates among individuals...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a $577,531 Project Grant effective March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct multiomics research examining the cellular mechanisms of fentanyl-induced opioid overdose. The project will generate the first single-nucleus RNA sequencing (snRNA-seq) and single-nucleus Assay for Transposase-Accessible Chromatin (snATAC-seq) paired multiomics data from two critical brainstem respiratory control regions—the preBötzinger complex/ventral respiratory group (PreBöt/VRG) and parabrachial/Kölliker-Fuse nuclei (PB/KFN)—in 40 fentanyl overdose decedents and 40 matched controls. This research addresses the biological mechanisms underlying opioid-induced respiratory depression, the primary cause of overdose death, by characterizing the relationship between chromatin accessibility and gene expression patterns in understudied brainstem regions implicated in respiratory control. The project will produce comprehensive multiomics datasets and analytical outputs that identify cell-type-specific signatures and potentially targetable genes contributing to fentanyl overdose vulnerability. By integrating single-nucleus paired transcriptomic and epigenomic analyses rather than relying on bulk tissue approaches, the research will provide novel mechanistic insights into individual cellular differences in overdose susceptibility. The award period extends through November 30, 2030, with work performed at The Washington University's Office of Sponsored Research Services Division in Missouri.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $577.5k | 3/12/26 |